Bicycle Therapeutics is a clinical-stage company developing nuzefatide pevedotin, a small peptide that delivers chemotherapy to tumors with EphA2, for pancreatic cancer; it is not approved.
Bicycle's case rests on nuzefatide, an EphA2-targeting drug conjugate, after zelenectide was deprioritized. Its recurrent pancreatic cancer Phase 2 first dosed a patient in April 2026; further updates are expected in 2027, while supporting pancreatic activity remains preclinical. Randomized Duravelo-2 survival data are now expected in the second half of 2027. Following workforce reductions, cash of $469.9 million at September 30, 2026 supports management's expected runway into 2030.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Nuzefatide shows activity in recurrent pancreatic cancer
Do recurrent pancreatic cancer patient results support nuzefatide's activity and tolerability?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Bicycle awaits pancreatic cancer results; Duravelo-2 survival data now expected in 2027
Zelenectide pevedotin's mUC randomized Phase 2 data will determine whether BCYC can rebuild a registration path after regulators rejected its original trial design
Bicycle's pivot to nuzefatide in EphA2+ solid tumors hinges on whether Phase 2 PDAC efficacy data confirm the early mUC signal as a platform-defining result
Regulatory rejection of zelenectide forces a pivot to early-stage EphA2 radiopharmaceuticals; whether BRC data validates this new platform bet is the defining question
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Gastrointestinal cancers, Other cancers, Neurology and pain, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.